Diabetes Mellitus as a Risk Factor of Interval Colon Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410871" target="_blank" >RIV/00216208:11130/20:10410871 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/20:10410871

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=qaiJ1xKwBH" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=qaiJ1xKwBH</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000501550" target="_blank" >10.1159/000501550</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Diabetes Mellitus as a Risk Factor of Interval Colon Cancer

Popis výsledku v původním jazyce

The article published by Laish et al. presented the results of a retrospective study that focused on interval colorectal cancer (CRC). Two of the main findings of the study were that patients with interval CRC tend to be older and diabetic. The authors suggested that more careful or more frequent screening be performed for determining pre-malignant lesions in those patients. The study team collected and analyzed a large amount of data, leading to an interesting and important debate. Nevertheless, we would like to make 2 comments that may contribute to further detailed discussions of the issue. (1) As in most other CRC-related studies, in the analysis, the authors considered diabetes mellitus as one disease. But diabetes mellitus is a group of metabolic diseases resulting from various pathogenic defects, which may be treated in different ways. The most common type 2 diabetes is associated with insulin resistance, one of the possible CRC risk factors; while in patients with the second most common type 1 diabetes, we can presume its longer duration at the time of the CRC diagnosis, which is another risk factor suspected of playing a role in the development of CRC. Therefore, it would be interesting to distinguish these 2 types of diabetes at least between patients and analyze them separately. (2) Another factor that would be worthy of analysis is the presence of insulin therapy, especially in type 2 diabetes mellitus. It was suggested that chronic insulin therapy is associated with an increased colorectal adenoma risk among type 2 diabetes patients. On the contrary, metformin, the most commonly used oral antidiabetic drug, may have a preventive effect in relation to CRC [4]. Therefore, this drug would also be an interesting target for detailed analysis. With great respect, we suggest that these comments are taken into consideration if the continuation of the study is planned.

Název v anglickém jazyce

Diabetes Mellitus as a Risk Factor of Interval Colon Cancer

Popis výsledku anglicky

The article published by Laish et al. presented the results of a retrospective study that focused on interval colorectal cancer (CRC). Two of the main findings of the study were that patients with interval CRC tend to be older and diabetic. The authors suggested that more careful or more frequent screening be performed for determining pre-malignant lesions in those patients. The study team collected and analyzed a large amount of data, leading to an interesting and important debate. Nevertheless, we would like to make 2 comments that may contribute to further detailed discussions of the issue. (1) As in most other CRC-related studies, in the analysis, the authors considered diabetes mellitus as one disease. But diabetes mellitus is a group of metabolic diseases resulting from various pathogenic defects, which may be treated in different ways. The most common type 2 diabetes is associated with insulin resistance, one of the possible CRC risk factors; while in patients with the second most common type 1 diabetes, we can presume its longer duration at the time of the CRC diagnosis, which is another risk factor suspected of playing a role in the development of CRC. Therefore, it would be interesting to distinguish these 2 types of diabetes at least between patients and analyze them separately. (2) Another factor that would be worthy of analysis is the presence of insulin therapy, especially in type 2 diabetes mellitus. It was suggested that chronic insulin therapy is associated with an increased colorectal adenoma risk among type 2 diabetes patients. On the contrary, metformin, the most commonly used oral antidiabetic drug, may have a preventive effect in relation to CRC [4]. Therefore, this drug would also be an interesting target for detailed analysis. With great respect, we suggest that these comments are taken into consideration if the continuation of the study is planned.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Digestive Diseases

ISSN

0257-2753

e-ISSN

—

Svazek periodika

38

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

1

Strana od-do

31

Kód UT WoS článku

000508186000005

EID výsledku v databázi Scopus

2-s2.0-85069648349